Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DMB-3111
- Development stage
- Phase 1
- Lead developer
- Meiji Seika Pharma
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
DMB-3111 is a biosimilar of trastuzumab, a monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2/ERBB2). It is being jointly developed by Meiji Seika Pharma (Japan) and Dong-A Socio Holdings (Korea). Like the reference product trastuzumab, DMB-3111 binds to HER2 receptors on tumor cells and mediates its antitumor effects primarily through antibody-dependent cell-mediated cytotoxicity (ADCC) and inhibition of HER2 signaling. The drug has demonstrated bioequivalence to trastuzumab in pharmacokinetics, safety, and immunogenicity studies in healthy volunteers. Its primary indications under development are HER2-positive breast cancer and gastric cancer[1][3][4].
- Other names
- trastuzumab biosimilar
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on DMB-3111.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DMB-3111.